View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
  3. Deal News
November 11, 2021

CooperCompanies signs agreement to buy Generate Life Sciences for $1.6bn

CooperCompanies produces fertility and genomic products for women’s healthcare.

Global medical device company CooperCompanies has signed a definitive agreement with private investment firm GI Partners to acquire Generate Life Sciences in a deal valued at about $1.6bn.

Generate Life Sciences provides services that include reproductive, medical devices, genetic screening, fertility cryopreservation and healthcare technology.

It also provides newborn stem cell storage, such as blood and tissue from the umbilical cord, services as well as fertility treatment donor eggs and sperm.

CooperCompanies operates through two business units, CooperVision and CooperSurgical, and provides a broad range of products and services to advance vision care and the health of babies, women and families.

It produces contact lenses, medical devices, and fertility and genomic products for women’s healthcare.

Through this acquisition, CooperSurgical will be able to expand its fertility as well as labour and delivery offerings.

CooperCompanies president and CEO Al White said: “This acquisition is a strong strategic fit for CooperSurgical as it allows us to better serve fertility clinics and Ob/Gyns with a more extensive suite of products and services.

“As a leader in women’s healthcare, this is an important addition to our existing offerings and allows us to leverage our infrastructure and expertise, including our sales forces’ strong clinical reputation and educational capabilities.”

The transaction, which is subject to customary closing conditions, including regulatory clearance, is expected to be completed in the company’s first fiscal quarter next year.

As of 30 September, Generate Life Sciences reported trailing 12-month revenues of about $250m.

GI Partners managing director Dave Kreter said: “With the combination of these two leading companies we had a vision to create and build a platform that could address the personal desires of families’ reproductive and stem cell needs.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network